Q1 2023 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Conclusions Financial performance Immunology ianalumab - BAFF-R inhibitor Appendix Innovation: Clinical trials Neuroscience Oncology ianalumab - BAFF-R inhibitor References Abbreviations Other Indication NCT05349214 NEPTUNUS-2 (CVAY736A2302) Sjögren's syndrome Indication NCT05350072 NEPTUNUS-1 (CVAY736A2301) Sjögren's syndrome Phase Phase 3 Phase Phase 3 Patients 489 Patients 285 Primary Outcome Change from baseline in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo Measures Primary Outcome Measures Target Patients Arms Intervention Arm 1: Experimental - ianalumab exposure level 1 Arm 2: Experimental - ianalumab exposure level 2 Arm 3: Placebo comparator Patients with active Sjogren's syndrome Arms Change from baseline in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo Arm 1: Experimental - ianalumab Intervention Arm 2: Placebo comparator Target Patients Patients with active Sjogren's syndrome Readout Milestone(s) Primary 2026 Publication TBD Readout Milestone(s) Primary 2026 Publication TBD 58 Investor Relations | Q1 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation